Singapore’s ambition to become a biopharmaceutical manufacturing hub just got a big boost. US pharmaceutical giant MSD has opened a new packaging facility at its site in Tuas for its immunotherapy drug KEYTRUDA and HPV vaccine GARDASIL. The company also broke ground on a facility to produce next-generation inhalers. This is all part of MSD’s $700-million five-year investment in Singapore, expected to create more than 100 new jobs.
Subscribe to our channel here: https://cna.asia/youtubesub
Subscribe to our news service on Telegram: https://cna.asia/telegram
CNA Lifestyle: http://www.cnalifestyle.com